SCA15 Due to Large ITPR1 Deletions in a Cohort of 333 White Families With Dominant Ataxia

Cecilia Marelli, MD; Joyce van de Leemput, PhD; Janel O. Johnson, MS; Francois Tison, MD; Christel Thauvin-Robinet, MD, PhD; Fabienne Picard, MD; Christine Tranchant, MD; Dena G. Hernandez, MS; Bernard Huttin, MD; Jacques Bouliat, MD; Iban Sangla, MD; Christian Marescaux, MD; Serge Briqué, MD; Hélène Dollfus, MD; Sampath Arepalli, BS; Isabelle Benattu, MD; Elisabeth Ollagnon, MD; Sylvie Forlani, PhD; John Hardy, PhD; Giovanni Stevanin, PhD; Alexandra Dürr, MD, PhD; Andrew Singleton, PhD; Alexis Brice, MD

Background: Deletions in ITPR1, coding for the inositol-triphosphate receptor type 1, have been recently identified in spinocerebellar ataxia type 15 (SCA15).

Objective: To determine the frequency and the phenotypic spectrum of SCA15.

Design: Taqman polymerase chain reaction (258 index cases) or single-nucleotide polymorphism genome-wide genotyping (75 index cases).

Setting: A collaboration between the Centre de Recherche de l’Institut de Cerveau et de la Moelle Epinière of the Salpêtrière Hospital (Paris, France) and the Molecular Genetics Unit of the National Institute of Aging (Bethesda, Maryland).

Patients: Index cases of 333 families with autosomal dominant cerebellar ataxia negative for CAG repeat expansions in coding exons.

Main Outcome Measures: Detection of ITPR1 copy number alterations.

Results: A deletion of ITPR1 was found in 6 of 333 families (1.8%), corresponding to 13 patients with SCA15. Age at onset ranged from 18 to 66 years (mean [SD] age, 35 [16] years). The symptom at onset was cerebellar gait ataxia, except in 1 patient with isolated upper limb tremor. Although families were tested irrespective of their phenotype, patients with SCA15 had a homogeneous phenotype and were characterized by a slowly progressive cerebellar ataxia. However, pyramidal signs (2 patients) and mild cognitive problems (2 patients) were occasionally present. Radiologic findings showed global or predominant vermian cerebellar atrophy in all patients.

Conclusions: In this series, ITPR1 deletions were rare and accounted for approximately 1% of all autosomal dominant cerebellar ataxias. The SCA15 phenotype mostly consists of a slowly progressive isolated cerebellar ataxia with variable age at onset; an additional pyramidal syndrome and problems in executive functions may be present.

Arch Neurol. 2011;68(5):637-643

Autosomal dominant cerebellar ataxias (ADCAs) are a clinically and genetically heterogeneous group of progressive diseases characterized by cerebellar degeneration, often accompanied by degenerative changes in the brainstem, basal ganglia, cerebral cortex, spinal cord, and peripheral nervous system. To date, 28 genetic loci have been linked to ADCAs, and, among these, 18 genes have been identified. However, the underlying cause of disease in up to 50% of patients with ADCAs remains unknown.

Based on the molecular mechanism, 3 major ADCA classes are considered: the so-called polyglutamine diseases, caused by translated CAG repeat expansions (spinocerebellar ataxia [SCA] type 1, SCA2, SCA3, SCA6, SCA7, SCA17, and dentatorubral-pallidoluysian atrophy); ADCAs due to repeat expansions falling outside the coding region of the respective genes (SCA8, SCA10, SCA12, and purato-phine); and ADCAs caused by conventional mutations (SCA5, SCA11, SCA13, SCA14, SCA20, SCA27, and SCA28).

Recently, deletions in ITPR1, coding for the inositol-triphosphate receptor type 1 (ITPR1), have been identified in SCA15. Deletions were found initially in 3 SCA15-positive families and then in 2 Japanese families previously thought to have a distinct disease (SCA16)6,8; a missense mutation was identified in another Japanese family. Therefore, SCA15 and SCA16 are actually the same disease: any family with an ITPR1 mutation should be regarded as...
having SCA15, whereas SCA16 should become a "vacant SCA."9

The phenotype in the 10 SCA15-positive families described so far is that of an almost pure, slowly progressive cerebellar ataxia. Brain magnetic resonance imaging (MRI) showed marked, predominantly vermian, cerebellar atrophy.10-15 We report genetic and clinical data from 6 families with 13 patients carrying ITPR1 deletions and estimate the relative frequency of this genetic entity.

METHODS

This study was approved by the local bioethics committee (Comité Consultatif pour la Protection des Personnes et la Recherche Biomedicale Paris-Necker). Written informed consent was obtained from all participating members of the families before blood samples were collected for DNA extraction. DNA was stored in the DNA and Cell Bank at the Pitié-Salpêtrière Hospital in Paris.

PATIENTS

We screened for ITPR1 rearrangements in 333 unrelated index cases of ADCA. Age at onset ranged from 2 to 70 years (mean [SD] age, 43.7 [20] years). The study population included 86 index cases with pure cerebellar ataxia, 243 patients with a complex phenotype, and 4 individuals for whom the precise phenotype was not available.

Additional signs found in the index cases with complicated ADCA included in this series were alteration of vibration sense (n=79), pyramidal syndrome (n=72), cognitive impairment (n=72), dysphagia (n=55), electromyography-confirmed neuropathopathy (n=35), abnormal movements (n=26), ophthalmoplegia (n=25), Parkinsonism (n=19), mental retardation (n=12), macular alterations (n=5), and optic atrophy (n=3). Most participants were of western European origin (n=307).

CAG repeat expansions in the SCA1, SCA2, SCA3, SCA6, SCA7, SCA17, and dentatorubral-pallidoluysian atrophy (DRPLA) genes were excluded in all patients; repeat expansions responsible for SCA10 were excluded in 118 patients and for SCA12 in 243 patients. Also, SCA5 was excluded in 232 individuals, SCA11 in 61, SCA14 in 197, SCA13 in 202, and SCA28 in 238.

Individual 020 in family LYO-210 was initially referred as clinically affected, but molecular analysis did not find a deletion of ITPR1, despite identification of an ITPR1 deletion in affected family members. This individual was subsequently re-examined by one of us (C.M.) and was diagnosed as having a generalized dystonic and hyperkinetic syndrome. Onset of dystonic symptoms was at age 46 years. Neurologic examination at age 60 years revealed orofacial dystonia with blepharospasm and facial grimaces, limb dystonic postures, and inconstant hyperkinetic movements; except for mild difficulty in the heel/knee task, no other signs of cerebellar involvement were present, and the patient did not note gait disequilibrium or speech difficulties. Brain MRI, performed 14 years after disease onset, showed a very mild cerebellar vermis atrophy. He was treated with anticholinergic drugs and botulinum toxin injections in the orbicular muscles.

DETECTION OF COPY NUMBER ALTERATIONS AT THE ITPR1 LOCUS

Two different techniques were applied to detect ITPR1 gene dosage anomalies. Two hundred fifty-eight index cases of families for which DNA from only 1 affected member was available were analyzed using a Taqman assay and an ABI 7900HT (Applied Biosystems, Foster City, California); gene dosage analyses were performed for exon 10 using β-globin as an endogenous reference gene, and positive results were confirmed using single nucleotide polymorphism (SNP) chips as per the manufacturer’s protocol (Illumina 610-Quad; Illumina Inc, San Diego, California). Seventy-five index cases from families in which the DNA of more than 1 affected member was available were analyzed by genome-wide SNP genotyping using human genotyping chips (CNV370-Quad v3.0; Illumina Inc). Segregation analyses were performed using Taqman polymerase chain reaction in all available family relatives of index patients found to be carriers of ITPR1 copy number changes.

RESULTS

We found 6 index cases harboring an ITPR1 deletion. The availability of additional patients in 4 families allowed us to confirm cosegregation of the disease with the mutation. We collected and studied 13 patients with SCA15 (Figure 1).

The main clinical features of the 13 patients with SCA15 are given in the Table. All the families were of French origin. Age at onset ranged from 18 to 66 years (mean [SD] age, 35 [16] years); disease duration ranged from 3 to 43 years (mean [SD], 23 [13] years).

The main presenting symptom was cerebellar gait ataxia (12 of 13 patients) that was associated with upper limb postural tremor in 3 patients and with a pyramidal syndrome in 1 patient; 1 patient presented with isolated upper limb postural tremor. Almost all the patients subsequently developed a global cerebellar syndrome with gait and limb ataxia (13 of 13), ocular movement abnormalities (10 of 11), and dysarthria (11 of 12), which remains the main clinical finding at all stages of the disease. Ocular abnormalities were homogeneous and were characterized by horizontal gaze-evoked nystagmus and saccadic pursuits; saccadic velocity was preserved. Four patients (BOR-279-1, BOR-279-5, MAR-589-9, and MAR-589-11) reported an intermittent diplopia that disappeared in the following disease course in 3 patients. Postural tremor of the upper limbs was variably associated with disease progression: of the 4 patients with upper limb tremor at disease onset, only 2 still presented this sign at follow-up; in 1 patient, upper limb tremor appeared in a later stage of the disease. None of the patients had head tremor or titubation.

In addition to cerebellar ataxia, pyramidal signs with enhanced reflexes and the Babinski sign were observed.
in the 2 patients from family LYO-210. Mild swallowing difficulties were reported by 2 other patients more than 30 years after onset of the disease. Although the Mini-Mental State Examination result was normal in 2 patients, it was slightly altered in 2 others (patients EPI-21-2 and EPI-21-7), with a score of 26 of 30 and 27 of 30 at ages 68 and 50 years, respectively, more than 25 years after disease onset. Moreover, patient EPI-21-7 had a low IQ using the Wechsler Adult Intelligence Scale (global IQ=84, verbal IQ=79, and performance IQ=93), and a further neuropsychological evaluation confirmed slightly worsened executive and attentive problems. Only 1 patient had a formal electromyographic examination, which had normal findings; in addition, none of the patients presented a deep sensory alteration or reduced or abolished reflexes, indicative of posterior column or peripheral nerve involvement. No urinary symptoms or extrapyramidal signs were found.

Progression of the disease was particularly slow, and disease severity was only moderate in most patients (disability score of 1-4 on a 1-7 scale); only the 2 patients with more than 40 years of disease duration needed help to walk (disability score=4), but they were still ambulatory.

Brain MRI was available for 11 patients showing cerebellar atrophy (Figure 2), with a predominant dorsal vermis involvement in 2 patients (Figure 3). In 2 patients, only a brain computed tomographic scan was available, showing cerebellar atrophy.

**COMMENT**

Spinocerebellar ataxia type 15 is a rare form of ADCA. In this cohort of patients with ADCAs excluded for mutations in major ADCA genes, the frequency of ITPR1 deletions is 1.8% (6 of 333), and it increases to 7.0% (6 of 86) considering the subgroup of families with pure cerebellar ataxia or minimal additional signs. Considering all ADCA cases and that known polyglutamine expansions cause approximately 50% of the ADCAs, the frequency of ITPR1 deletions decreases to approximately 0.9%. The frequency we found is similar to the 2.7% recently reported in a series of 73 nonpolyglutamine ADCA–positive families. In this latter study, ITPR1 gene deletions were searched using the multiplex ligation–dependent probe amplification test, whereas in the present study, Taqman polymerase chain reaction was performed in the main subgroup of patients, with amplification limited to exon 10. An underestimation of SCA15 frequency could, therefore, have occurred because it is plausible that deletion may not extend to exon 10; ac-
tually, in 1 of 6 families (family MAR-588) analyzed by genome-wide SNP genotyping, the deletion terminated at approximately exon 10 and failed to be detected by Taqman polymerase chain reaction during segregation analysis. Previous studies and the present genome-wide SNP genotyping on 75 families show that, up to now, large deletions almost constantly involve the first 10 exons of ITPRI. This rearrangement, predicted to involve the N-terminal inositol triphosphate–binding domain, has been, therefore, proposed as a minimal critical region for SCA15; however, the case of family MAR-588 shows that careful attention should be taken in targeting it for diagnostic analysis.

We did not search for point mutations in ITPRI, although a Japanese family harboring a P1059L missense mutation and an individual with a V494I missense mutation have been described. However, pyramidal involvement with the Babinski sign was present in 2 patients, in 1 at the onset of disease; because milder pyramidal signs were also described in 3 previously reported SCA15 cases, they could be considered part of the clinical spectrum of the disease in a few patients. On the contrary, peripheral neuropathy, previously reported in the SCA15-positive Japanese family with a missense mutation, was not present in any of the present patients. The occurrence of impairment of cognitive functions, possibly present in 2 patients on the

| Table. Clinical Characteristics of 13 Patients With ITPRI Deletions |
|----------------|----------------|----------------|----------------|----------------|----------------|
| Variable       | LYO-210        | EPI-21         | BOR-279        | MAR-588        | SAL-153        |
| Patient No./sex| 14/M           | 16/M           | 2/M            | 5/F            | 7/M            |
| Age at onset, y| 48             | 66             | 25             | 20             | 23             |
| Symptoms at onset | Gait ataxia, stiffness | Gait ataxia | Gait ataxia | Gait ataxia | Gait ataxia |
| Disease duration, y | 14            | 14             | 31             | 27             | 6              |
| Disability score | ND             | 3              | 4              | 3              | 1              |
| Gait ataxia     | +              | +              | +              | +              | +              |
| Limb ataxia     | +              | +              | +              | +              | +              |
| Lysthria        | +              | +              | +              | ND             | +              |
| Nystagmus       | ND             | H, GE          | +              | +              | +              |
| Saccadic pursuit| ND             | ND             | +              | +              | +              |
| Postural tremor | ND             | UL             | ND             | ND             | ND             |
| Swallowing      | ND             | −              | ND             | ND             | ND             |
| Pyramidal signs | −              | +              | −              | +              | −              |
| Cerebellar atrophy, MRI | ND            | ND             | ND             | ND             | ND             |
| Abbreviations: EMG, electromyography; GE, gaze evoked; H, horizontal; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; N, normal; NA, not applicable; ND, not determined; UN, upper limb; +, present; −, absent. |

©2011 American Medical Association. All rights reserved.
basis of Mini-Mental State Examination and Wechsler Adult Intelligence Scale scores, was confirmed in 1 patient showing progressive alteration of executive functions and was also recently reported in 2 other patients.\textsuperscript{14} We cannot, therefore, exclude possible mild cognitive involvement in a few patients with SCA15.

In the present series, ocular involvement is discrete and is characterized by the combination of gaze-evoked nystagmus and saccadic pursuit. An alteration of the vestibulo-ocular reflex has been reported in the original Australian family with SCA15.\textsuperscript{10} The combination of these ocular abnormalities points toward involvement of the flocculus-paraflocculus regions and of the dorsal vermis,\textsuperscript{19} which is in accord with MRI findings. Because diplopia had mostly disappeared at the last follow-up visit and was not associated with ophthalmoplegia, we considered it a subjective symptom due to a defect in stabilizing retinal images and not a sign of involvement of extracerebellar structures.

The boundaries between a pure and a complex cerebellar ataxia are not always simple to define. In SCA15, although we and other researchers\textsuperscript{13} show that other systems may be involved, this occurs in only a few patients, and cerebellar involvement largely predominates at clinical and radiologic levels. Compared with the constant and marked multisystemic involvement occurring in most polyglutamine ADCAs, SCA15 appears as pure cerebellar ataxia, sometimes associated with minimal extracerebellar signs. We did not find a correlation between the clinical phenotype and the extension of ITPRI deletion or the involvement of different contiguous genes.

The radiologic findings of the present patients with SCA15 were also homogeneous and showed cerebellar, predominantly vermian, atrophy without cortical or brainstem involvement. Serial MRIs were not performed, and we could not determine the progression of cerebellar atrophy and its correlation with clinical findings.

The pathogenesis of ataxia due to ITPRI deletions remains to be elucidated. ITPRI is highly expressed in Purkinje cells and mediates Ca\textsuperscript{2+} release from the endoplasmic reticulum in various neurons, including CA1, basal ganglia, and thalamic and Purkinje neurons.\textsuperscript{17,18} Homozygous \textit{Itpr1} knockout mice develop severe ataxia and epilepsy and die early in development\textsuperscript{19,20}, a similar but less severe phenotype was found in the \textit{opt} mouse, harboring a homozygous in-frame deletion of exons 43 and 44 of \textit{Itpr1},\textsuperscript{21} and in a mouse with a homozygous in-frame deletion of 18 base pairs in exon 36.\textsuperscript{6} A further mouse model, \textit{Itpr1} heterozygous knockout, presented isolated late-onset mild ataxia.\textsuperscript{22} In these models, no apparent morphologic abnormalities were found. Note that none of the individuals with SCA15 due to ITPRI heterozygous mutations had epilepsy or abnormal electroencephalographic findings.

Evidence suggests that impairment of the inositol 1,4,5-triphosphate pathway is implicated in the pathogenesis of different types of ataxia. In 2 SCA1 mouse models, \textit{itpr1} was among the neuronal genes downregulated at a very early stage in pathogenesis, and this downregulation required nuclear localization of the mutant ataxin-1.\textsuperscript{23} The ITPRI seems to specifically interact also with the mutated form of the proteins ataxin-3\textsuperscript{24} and ataxin-2,\textsuperscript{25} causing SCA3 and SCA2, respectively. Moreover, mutation in carbonic anhydrase–related protein 8, which inhibits the binding of inositol triphosphate to the ITPRI, has been recently shown to cause an autosomal dominant ataxia associated with mild mental retardation and predisposition to quadrupedal gait in humans.\textsuperscript{26}

Recently, the ITPRI receptor signaling cascade has been found to underlie the coincidence detection system in Purkinje cells, responsible for cerebellar plasticity; the dysfunction of this system has been proposed to be the unifying feature of the many genes that cause cerebellar ataxia.
and interact with ITPR1. Moreover, ITPR1 interacts with the huntingtin protein, mutated in Huntington disease, and it is, therefore, involved also in the pathogenesis of nonataxic neurodegenerative diseases.28

In conclusion, SCA15 due to deletion in the ITPR1 gene is uncommon; the relevance of SCA15 due to ITPR1 point mutations remains to be determined. Although the main phenotype is a cerebellar ataxic syndrome associated with severe cerebellar atrophy, as seen by brain MRI, pyramidal signs and executive dysfunctions can also be rarely found and, therefore, should not be considered exclusion criteria. Disease progression is slow, and age at onset is remarkably variable. Moreover, it will be interesting to better understand the pathogenic mechanism of ataxia due to dysfunction of the ITPR1 pathway and cerebellar plasticity and to see whether other ataxias may also be due to impairment of the same signaling cascade.

Accepted for Publication: October 6, 2010.

Author Affiliations: Université Pierre et Marie Curie-Paris6, Centre de Recherche de l’Institut du Cerveau et de la Moelle Épinière, UMR-S975, Paris, France (Drs Marelli, Stevanin, Durr, and Brice); Inserm, U975, CNRS, UMR 7225, Paris (Drs Marelli, Stevanin, Durr, and Brice); Department of Genetics and Cyto genetics, Hôpital de la Salpêtrière, Paris (Drs Marelli, Stevanin, Durr, and Brice); Molecular Genetics Unit, National Institute on Aging, National Institutes of Health, Bethesda, Maryland (Drs van de Leemput and Singleton and Ms Johnson, Hernandez, and Arepalli); Department of Molecular Neuroscience, Institute of Neurology, University College London, London, United Kingdom (Drs van de Leemput and Hardy and Mss Johnson and Hernandez); Department of Neurology, Hôpital Universitaire de Bordeaux, Bordeaux, France (Dr Tison); Department of Genetics, CHU Dijon, France (Dr Thauvin-Robinet); Department of Neurology, University Hospital and Medical School of Geneva, Geneva, Switzerland (Dr Picard); Department of Neurology, Hôpital Civil, Strasbourg, France (Drs Tranchant and Marescaux); Department of Neurology, Centre Hospitalier Jean Monnet, Epinal, France (Dr Huttin); Department of Neurology, Hôpital de Fleyriat, Bourg en Bresse, France (Dr Boulliat); Department of Neurology, Hôpital de la Timone, Marseille, France (Dr Sangla); Laboratoire Physiopathologie des Syndromes Rares Héréditaires, AVENIR-Inserm, EA3949, Université Louis Pasteur, Strasbourg (Dr Dollfus); Department of Neurology, Hôpital Général, CHU Dijon (Dr Benatru); Department of Genetics, Hôpital de la Croix Rousse, Lyon, France (Dr Ollagnon); and DNA and Cell Bank, Université Pierre et Marie Curie-Paris6, Centre de Recherche de l’Institut du Cerveau et de la Moelle Épinière, Centre de Recherche de l’Institut du Cerveau et de la Moelle Épinière, 47 Bd de l’Hôpital 75651 Paris CEDEX 13, France (alexis.brice @upmc.fr).

Author Contributions: Study concept and design: Hernandez, Hardy, Singleton, and Brice. Acquisition of data: Marelli, van de Leemput, Johnson, Tison, Thauvin-Robinet, Picard, Tranchant, Hernandez, Hut tin, Boulliat, Sangla, Marescaux, Brique, Dollfus, Arepalli, Benatu r, Ollagnon, Forlani, Stevanin, Singleton, and Brice. Analysis and interpretation of data: Marelli, van de Leemput, Johnson, Hernandez, Hardy, Stevanin, Durr, and Singleton. Drafting of the manuscript: Marelli, van de Leemput, Tison, Picard, Hut tin, Boulliat, Marescaux, Brique, Dollfus, Arepalli, Benatru, Ollagnon, and Forlani. Critical revision of the manuscript for important intellectual content: Marelli, Johnson, Tison, Thauvin-Robinet, Tranchant, Hernandez, Sangla, Hardy, Stevanin, Durr, Singleton, and Brice. Obtaining funding: Hernandez, Ol lagnon, Stevanin, Durr, Singleton, and Brice. Administrative, technical, and material support: Marelli, van de Leemput, Johnson, Picard, Boulliat, Arepalli, and Forlani. Study supervision: Hernandez, Hardy, Stevanin, Durr, Singleton, and Brice.

Financial Disclosure: None reported.

Funding/Support: This work was supported in part by the European Union (to the European Integrated Project on Spinocerebellar Ataxias Network), the Programme Hospitalier de Recherche Clinique (Dr Durr), and project Z01 AG00958-06 of the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services (Dr Singleton).

Online-Only Material: The eFigure is available at http://www.archneurol.com.

Additional Contributions: We thank the family members for their participation and the DNA and Cell Bank of the Centre de Recherche de l’Institut du Cerveau et de la Moelle Épinière (CRICM) for technical assistance.

REFERENCES
Announcement

Trial Registration Required. As a member of the International Committee of Medical Journal Editors (ICMJE), Archives of Neurology will require, as a condition of consideration for publication, registration of all trials in a public trials registry (such as http://ClinicalTrials.gov). Trials must be registered at or before the onset of patient enrollment. The trial registration number should be supplied at the time of submission.

For details about this new policy, and for information on how the ICMJE defines a clinical trial, see the editorials by DeAngelis et al in the September 8, 2004 (2004; 292:1363-1364) and June 15, 2005 (2005;293:2927-2929) issues of JAMA. Also see the Instructions to Authors on our Web site: www.archneurol.com.